Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damage

Pflugers Arch. 2022 Oct;474(10):1069-1076. doi: 10.1007/s00424-022-02726-3. Epub 2022 Jul 22.

Abstract

Proinflammatory cytokines target vascular endothelial cells during COVID-19 infections. In particular, the endothelial glycocalyx (eGC), a proteoglycan-rich layer on top of endothelial cells, was identified as a vulnerable, vasoprotective structure during infections. Thus, eGC damage can be seen as a hallmark in the development of endothelial dysfunction and inflammatory processes. Using sera derived from patients suffering from COVID-19, we could demonstrate that the eGC became progressively worse in relation to disease severity (mild vs severe course) and in correlation to IL-6 levels. This could be prevented by administering low doses of spironolactone, a well-known and highly specific aldosterone receptor antagonist. Our results confirm that SARS-CoV-2 infections cause eGC damage and endothelial dysfunction and we outline the underlying mechanisms and suggest potential therapeutic options.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 Drug Treatment*
  • COVID-19* / blood
  • COVID-19* / pathology
  • Cytokines / pharmacology
  • Endothelial Cells / drug effects
  • Endothelial Cells / pathology
  • Glycocalyx* / drug effects
  • Glycocalyx* / pathology
  • Humans
  • Interleukin-6 / blood
  • Mineralocorticoid Receptor Antagonists* / pharmacology
  • Mineralocorticoid Receptor Antagonists* / therapeutic use
  • Proteoglycans / analysis
  • Proteoglycans / blood
  • SARS-CoV-2*
  • Spironolactone* / pharmacology
  • Spironolactone* / therapeutic use

Substances

  • Cytokines
  • Interleukin-6
  • Mineralocorticoid Receptor Antagonists
  • Proteoglycans
  • Spironolactone